Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

The latest research advances demonstrate the potential of Regeneron’s diverse pipeline ... comparing odronextamab monotherapy to rituximab plus standard-of-care chemotherapies.